Oncolytics Approves Nevada Domestication, Adopts 2026 Incentive Plan and Appoints McAdory, Wu
On Jan. 15, 2026, Oncolytics shareholders approved relocating its domicile to Nevada via British Columbia and adopted its 2026 Incentive Award Plan, all expected by end of Q1 2026. It appointed John McAdory EVP of Strategy and Operations and Yujun Wu VP of Biostatistics to support pelareorep registration trials.
1. Special Meeting Voting Outcomes
On January 15, 2026, Oncolytics Biotech Inc. held a Special Meeting of Shareholders in San Diego where all three proposals from its December 9, 2025 management information circular were approved. The Continuance Resolution, authorizing the move from Alberta to British Columbia, passed with 85.21% support (14,994,075 votes for; 2,602,405 against). The Domestication Resolution, to re-domicile from British Columbia to Nevada, received 86.98% approval (15,304,574 for; 2,291,905 against). Shareholders also ratified the 2026 Incentive Award Plan with 76.77% in favor (13,508,657 for; 4,087,822 against). Oncolytics plans to complete both corporate continuances and to activate the new equity incentive program by the end of Q1 2026.
2. Strategic Re-domiciliation and Incentive Plan
The approved corporate continuance steps will transition Oncolytics from its Canadian origins—first moving its jurisdiction from Alberta to British Columbia, then from British Columbia to the State of Nevada. This dual-step domestication is designed to align the company’s legal framework with U.S. capital markets and regulatory requirements. Concurrently, the newly ratified 2026 Incentive Award Plan is contingent upon these moves and establishes a framework for granting stock options, restricted share units, and performance-based awards to attract and retain key personnel as Oncolytics advances its global clinical programs.
3. Executive Team Expansion for Pelareorep Development
Oncolytics has bolstered its leadership team to accelerate late-stage development of pelareorep in gastrointestinal cancers. John McAdory joined as Executive Vice President of Strategy and Operations, bringing over a decade of experience leading Phase 3 oncolytic virus trials at CG Oncology. Yujun Wu was hired as Vice President and Head of Biostatistics, formerly overseeing statistical strategy through Morphic Therapeutics’ acquisition by Eli Lilly and directing Takeda’s Phase 3 oncology programs. These appointments, together with last year’s additions of Chief Business Officer Andrew Aromando and CEO Jared Kelly’s elevation, complete a C-suite with proven regulatory and operational expertise ahead of pivotal registration trials in pancreatic, anal, and colorectal cancers.